- Mycosis fungoides and Sézary syndrome: Australian clinical practice statement.
- Mycosis fungoides and Sézary syndrome: Australian clinical practice statement.
- Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas.
- Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial.
- Laboratory quality assessment of candidate gene panel testing for acute myeloid leukaemia: a joint ALLG / RCPAQAP initiative.
- Automated digital enumeration of plasma cells in bone marrow trephine biopsies of multiple myeloma.
- Autologous stem cell transplantation for untreated transformed indolent B-cell lymphoma in first remission: an international, multi-centre propensity-score-matched study.
- Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study.
- DA-EPOCH-R in Burkitt Lymphoma: Is It Enough for High-Risk Disease?
- Characteristics and outcome of patients with relapsed/refractory Hodgkin lymphoma following front-line escalated BEACOPP-based chemotherapy: a report from the Australasian Lymphoma Alliance.
- Event free survival at 12 months (EFS12) in stage 1 DLBCL - a reassuring milestone?
- Outcomes and anticoagulation use for elderly patients that present with an Acute Hip Fracture: multi-centre, retrospective analysis.
- Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis.
- A RANDOMIZED PHASE 3 TRIAL OF ZANUBRUTINIB VERSUS IBRUTINIB IN SYMPTOMATIC WALDENSTRÖM MACROGLOBULINEMIA:THE ASPEN STUDY.
- Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: three years of follow-up.